marketcaparena
Search

    PBH

    Prestige Consumer Healthcare Inc.

    Company overview

    Market capitalization
    $2.22B
    Employees
    890
    Latest publication
    2026-09-29
    About Prestige Consumer Healthcare Inc.

    Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USD
    Total Revenue265,710,000USD281,617,000USD283,444,000USD274,114,000USD249,530,000USD296,755,000USD290,317,000USD283,548,000USD
    Cost Of Revenue129,522,000USD140,756,000USD126,075,000USD120,043,000USD114,381,000USD121,044,000USD129,268,000USD126,166,000USD
    Gross Profit136,188,000USD140,861,000USD157,369,000USD154,071,000USD135,149,000USD175,711,000USD161,049,000USD157,382,000USD
    Selling And Marketing Expenses34,668,000USD35,089,000USD40,055,000USD38,701,000USD34,937,000USD37,004,000USD37,945,000USD41,409,000USD
    General And Administrative Expenses43,303,000USD———————
    Total Operating Expenses83,668,000USD65,369,000USD74,878,000USD74,401,000USD63,393,000USD87,283,000USD69,087,000USD73,043,000USD
    Operating Income52,520,000USD75,492,000USD82,491,000USD79,670,000USD71,756,000USD88,428,000USD91,962,000USD84,339,000USD
    Total Other Income Expense Net-13,979,000USD-10,720,000USD-20,677,000USD-10,537,000USD-9,979,000USD-14,469,000USD-11,808,000USD-12,676,000USD
    Income Before Tax38,541,000USD64,772,000USD61,814,000USD69,133,000USD61,777,000USD73,959,000USD80,154,000USD71,663,000USD
    Income Tax Expense9,364,000USD10,844,000USD15,118,000USD26,922,000USD14,311,000USD23,831,000USD19,122,000USD17,286,000USD
    Net Income29,177,000USD53,928,000USD46,696,000USD42,211,000USD47,466,000USD50,128,000USD61,032,000USD54,377,000USD
    Selling General Administrative—30,280,000USD29,674,000USD28,037,000USD28,456,000USD27,050,000USD26,182,000USD26,067,000USD
    Interest Expense—11,428,000USD10,672,000USD10,036,000USD10,203,000USD10,759,000USD11,455,000USD12,281,000USD
    Net Interest Income—-11,428,000USD-10,672,000USD-10,036,000USD-10,203,000USD-10,759,000USD-11,455,000USD-12,281,000USD
    Tax Provision—10,844,000USD15,118,000USD26,922,000USD14,311,000USD23,831,000USD19,122,000USD17,286,000USD
    Net Income From Continuing Ops—53,928,000USD46,696,000USD42,211,000USD47,466,000USD50,128,000USD61,032,000USD54,377,000USD
    Ebit—76,200,000USD72,486,000USD79,169,000USD71,980,000USD84,718,000USD91,609,000USD83,944,000USD
    Ebitda—84,552,000USD80,078,000USD86,832,000USD79,646,000USD91,970,000USD98,477,000USD89,511,000USD
    Depreciation And Amortization—8,352,000USD7,592,000USD7,663,000USD7,666,000USD7,252,000USD6,868,000USD5,567,000USD
    Reconciled Depreciation—8,352,000USD7,592,000USD7,663,000USD7,666,000USD7,252,000USD6,868,000USD7,929,000USD
    Unclassified Operating Expenses——5,149,000USD7,663,000USD—23,229,000USD4,960,000USD5,567,000USD
    Interest Income——10,672,000USD10,036,000USD10,203,000USD10,759,000USD11,455,000USD12,281,000USD
    Net Income Applicable To Common Shares——46,696,000USD42,211,000USD47,466,000USD50,128,000USD61,032,000USD54,377,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USDFY 20182018-03-31 · USD
    Total Revenue1,088,705,000USD1,137,762,000USD1,125,357,000USD1,086,812,000USD943,365,000USD963,010,000USD975,777,000USD1,041,179,000USD
    Cost Of Revenue514,067,000USD503,299,000USD500,909,000USD466,166,000USD395,893,000USD410,787,000USD420,201,000USD464,674,000USD
    Gross Profit574,638,000USD634,463,000USD624,448,000USD620,646,000USD547,472,000USD552,223,000USD555,576,000USD576,505,000USD
    Selling General Administrative116,447,000USD108,209,000USD106,152,000USD107,459,000USD83,106,000USD89,112,000USD89,759,000USD184,925,000USD
    Selling And Marketing Expenses148,782,000USD155,723,000USD153,315,000USD157,343,000USD140,589,000USD147,194,000USD143,090,000USD147,286,000USD
    Total Operating Expenses265,228,999USD297,688,000USD282,019,000USD290,727,000USD250,070,000USD261,068,000USD259,896,000USD360,639,000USD
    Operating Income309,409,000USD336,775,000USD342,429,000USD329,919,000USD297,402,000USD291,155,000USD67,503,000USD215,866,000USD
    Interest Expense42,339,000USD47,632,000USD67,160,000USD64,287,000USD82,328,000USD96,566,000USD105,299,000USD106,267,000USD
    Net Interest Income-42,339,000USD-47,632,000USD-67,160,000USD-64,287,000USD-82,328,000USD-96,224,000USD-105,082,000USD-105,879,000USD
    Income Before Tax257,495,999USD284,189,000USD276,025,000USD262,458,000USD204,113,000USD191,151,000USD-38,055,000USD107,086,000USD
    Income Tax Expense67,195,000USD69,584,000USD66,686,000USD57,077,000USD39,431,000USD48,870,000USD-2,255,000USD-232,484,000USD
    Tax Provision67,195,000USD69,584,000USD66,686,000USD57,077,000USD39,431,000USD48,870,000USD-2,255,000USD-232,484,000USD
    Net Income190,301,000USD214,605,000USD209,339,000USD205,381,000USD164,682,000USD142,281,000USD-35,800,000USD339,570,000USD
    Net Income From Continuing Ops190,301,000USD214,605,000USD209,339,000USD205,381,000USD164,682,000USD142,281,000USD-35,800,000USD339,570,000USD
    Ebit299,834,999USD331,821,000USD343,185,000USD326,745,000USD286,441,000USD287,717,000USD67,027,000USD322,298,000USD
    Ebitda331,107,999USD361,994,000USD373,860,000USD358,837,000USD316,605,000USD325,498,000USD98,806,000USD355,724,000USD
    Depreciation And Amortization31,273,000USD30,173,000USD30,675,000USD32,092,000USD30,164,000USD37,781,000USD31,779,000USD33,426,000USD
    Reconciled Depreciation31,273,000USD30,173,000USD30,675,000USD32,092,000USD30,164,000USD28,995,000USD31,779,000USD33,426,000USD
    Total Other Income Expense Net-51,913,000USD-52,586,000USD-66,404,000USD-67,461,000USD-93,289,000USD-100,004,000USD-105,558,000USD-108,388,000USD
    Unclassified Operating Expenses—33,756,000USD22,552,000USD25,925,000USD26,375,000USD24,762,000USD27,047,000USD28,428,000USD
    Interest Income—47,632,000USD67,160,000USD64,287,000USD82,328,000USD342,000USD217,000USD388,000USD
    Net Income Applicable To Common Shares—214,605,000USD209,339,000USD205,381,000USD164,682,000USD142,281,000USD-35,800,000USD339,570,000USD
    Non Operating Income Net Other———-3,174,000USD-10,961,000USD-3,438,000USD-259,000USD-2,513,000USD
    Research Development———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USD
    Total Assets4,568,573,000USD3,547,570,000USD3,494,743,000USD3,442,280,000USD3,431,625,000USD3,402,218,000USD3,329,497,000USD3,316,885,000USD
    Cash And Equivalents89,127,000USD—62,373,000USD119,106,000USD139,502,000USD97,884,000USD50,874,000USD51,540,000USD
    Total Current Assets496,814,000USD431,484,000USD433,428,000USD497,411,000USD480,518,000USD448,328,000USD377,164,000USD380,708,000USD
    Other Current Assets30,117,000USD16,564,000USD17,005,000USD20,309,000USD19,485,000USD8,442,000USD7,500,000USD9,396,000USD
    Other Non Current Assets13,432,000USD———————
    Total Liabilities2,651,857,000USD———————
    Total Current Liabilities153,806,000USD120,924,000USD139,557,000USD134,604,000USD109,668,000USD106,623,000USD102,545,000USD106,906,000USD
    Other Non Current Liabilities5,587,000USD———————
    Total Stockholder Equity1,916,716,000USD1,887,516,000USD1,829,451,000USD1,824,969,000USD1,855,482,000USD1,834,897,000USD1,788,433,000USD1,731,761,000USD
    Total Equity Including Noncontrolling Interest1,916,716,000USD———————
    Short Long Term Debt10,450,000USD2,986,000USD——————
    Long Term Debt2,007,235,000USD993,953,000USD1,033,547,000USD993,146,000USD992,749,000USD992,357,000USD991,969,000USD1,051,586,000USD
    Net Receivables187,355,000USD191,920,000USD190,456,000USD199,000,000USD168,405,000USD194,293,000USD167,274,000USD163,547,000USD
    Inventory190,215,000USD159,132,000USD163,594,000USD158,996,000USD153,126,000USD147,709,000USD151,516,000USD156,225,000USD
    Property Plant Equipment Net143,218,000USD171,245,000USD174,738,000USD121,943,000USD124,940,000USD127,842,000USD108,125,000USD83,683,000USD
    Goodwill650,795,000USD———————
    Intangible Assets3,243,358,000USD2,299,605,000USD2,301,536,000USD2,291,073,000USD2,294,829,000USD2,295,350,000USD2,310,650,000USD2,316,542,000USD
    Accounts Payable36,849,000USD22,791,000USD42,946,000USD41,924,000USD22,206,000USD18,925,000USD19,506,000USD31,172,000USD
    Short Term Debt7,010,000USD12,552,000USD8,633,000USD8,620,000USD8,602,000USD8,537,000USD6,918,000USD2,651,000USD
    Common Stock563,000USD562,000USD562,000USD562,000USD561,000USD560,000USD559,000USD557,000USD
    Retained Earnings1,775,280,000USD1,746,103,000USD1,692,175,000USD1,645,479,000USD1,603,268,000USD1,555,802,000USD1,505,674,000USD1,444,642,000USD
    Accumulated Other Comprehensive Income-29,678,000USD-28,368,000USD-30,234,000USD-31,599,999USD-32,255,000USD-37,659,000USD-40,164,000USD-26,536,000USD
    Total Liab—1,660,054,000USD1,665,292,000USD1,617,311,000USD1,576,143,000USD1,567,321,000USD1,541,064,000USD1,585,124,000USD
    Other Current Liab—85,581,000USD87,512,000USD84,060,000USD73,408,000USD78,331,000USD75,685,000USD72,979,000USD
    Capital Stock—562,000USD562,000USD562,000USD561,000USD560,000USD559,000USD557,000USD
    Good Will—581,109,000USD581,248,000USD528,410,999USD528,314,000USD527,425,000USD527,219,000USD529,225,000USD
    Cash—63,868,000USD62,373,000USD119,106,000USD139,502,000USD97,884,000USD50,874,000USD51,540,000USD
    Cash And Short Term Investments—63,868,000USD62,373,000USD119,106,000USD139,502,000USD97,884,000USD50,874,000USD51,540,000USD
    Net Debt—981,560,000USD1,016,917,000USD921,918,000USD903,222,000USD946,366,000USD976,258,000USD1,009,340,000USD
    Short Long Term Debt Total—1,045,428,000USD1,079,290,000USD1,041,024,000USD1,042,724,000USD1,044,250,000USD1,027,132,000USD1,060,880,000USD
    Property Plant Equipment Gross—260,113,000USD174,738,000USD121,943,000USD124,940,000USD209,077,000USD108,125,000USD83,683,000USD
    Common Stock Shares Outstanding—47,686,000shares48,087,000shares49,264,000shares49,833,000shares50,080,000shares49,993,000shares49,998,000shares
    Non Current Assets Total—3,116,086,000USD3,061,315,000USD2,944,869,000USD2,951,107,000USD2,953,890,000USD2,952,333,000USD2,936,177,000USD
    Non Current Liabilities Total—1,539,130,000USD1,525,735,000USD1,482,707,000USD1,466,475,000USD1,460,698,000USD1,438,519,000USD1,478,218,000USD
    Non Current Liabilities Other—5,580,000USD5,747,000USD5,379,000USD5,406,000USD5,391,000USD5,029,000USD5,124,000USD
    Non Currrent Assets Other—2,170,000USD3,793,000USD3,442,000USD3,024,000USD3,273,000USD6,339,000USD6,727,000USD
    Net Working Capital—310,560,000USD293,871,000USD362,807,000USD370,850,000USD341,705,000USD274,619,000USD273,802,000USD
    Unclassified Non Current Assets—61,957,000USD——————
    Unclassified Current Liabilities—-2,986,000USD——5,452,000USD———
    Unclassified Non Current Liabilities—539,597,000USD486,441,000USD484,182,000USD468,320,000USD462,950,000USD441,521,000USD421,508,000USD
    Unclassified Equity—168,657,000USD166,386,000USD209,965,999USD283,347,000USD315,634,000USD321,805,000USD312,541,000USD
    Other Assets——3,793,000USD3,442,000USD3,024,000USD3,273,000USD6,339,000USD6,727,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Total Assets3,547,570,000USD3,402,218,000USD3,318,417,000USD3,353,729,000USD3,670,681,000USD3,429,273,000USD3,513,905,000USD3,441,036,000USD
    Intangible Assets2,299,605,000USD2,295,350,000USD2,320,583,000USD2,341,893,000USD2,696,635,000USD2,475,729,000USD2,479,391,000USD2,507,210,000USD
    Other Current Assets16,564,000USD8,442,000USD13,082,000USD4,117,000USD6,410,000USD7,903,000USD4,351,000USD9,482,000USD
    Total Liab1,660,054,000USD1,567,321,000USD1,663,333,000USD1,906,645,000USD2,093,070,000USD2,070,975,000USD2,342,934,000USD2,345,205,000USD
    Total Stockholder Equity1,887,516,000USD1,834,897,000USD1,655,084,000USD1,447,084,000USD1,577,611,000USD1,358,298,000USD1,170,971,000USD1,095,831,000USD
    Other Current Liab85,581,000USD78,331,000USD69,348,000USD77,567,000USD75,886,000USD63,694,000USD75,547,000USD70,331,000USD
    Common Stock562,000USD560,000USD555,000USD548,000USD544,000USD540,000USD538,000USD536,000USD
    Capital Stock562,000USD560,000USD555,000USD548,000USD544,000USD540,000USD538,000USD536,000USD
    Retained Earnings1,746,103,000USD1,555,802,000USD1,341,197,000USD1,131,858,000USD1,214,164,000USD1,008,783,000USD844,101,000USD701,820,000USD
    Good Will581,109,000USD527,425,000USD527,733,000USD527,553,000USD578,976,000USD578,079,000USD575,179,000USD578,583,000USD
    Cash63,868,000USD97,884,000USD46,469,000USD58,489,000USD27,185,000USD32,302,000USD94,760,000USD27,530,000USD
    Cash And Short Term Investments63,868,000USD97,884,000USD46,469,000USD58,489,000USD27,185,000USD32,302,000USD94,760,000USD27,530,000USD
    Total Current Assets431,484,000USD448,328,000USD375,043,000USD391,743,000USD293,267,000USD269,835,000USD365,654,000USD300,938,000USD
    Total Current Liabilities120,924,000USD106,623,000USD117,048,000USD160,715,000USD143,422,000USD122,138,000USD149,881,000USD126,979,000USD
    Net Debt981,560,000USD946,366,000USD1,093,187,000USD1,308,602,000USD1,479,174,000USD1,482,319,000USD1,671,875,000USD1,771,068,000USD
    Short Term Debt12,552,000USD8,537,000USD6,152,000USD9,760,000USD9,112,000USD8,446,000USD6,832,000USD0USD
    Short Long Term Debt2,986,000USD———————
    Short Long Term Debt Total1,045,428,000USD1,044,250,000USD1,139,656,000USD1,367,091,000USD1,506,359,000USD1,514,621,000USD1,766,635,000USD1,798,598,000USD
    Long Term Debt993,953,000USD992,357,000USD1,125,804,000USD1,345,788,000USD1,476,658,000USD1,479,653,000USD1,730,300,000USD1,798,598,000USD
    Net Receivables191,920,000USD194,293,000USD176,775,000USD167,016,000USD139,330,000USD114,671,000USD150,517,000USD148,787,000USD
    Inventory159,132,000USD147,709,000USD138,717,000USD162,121,000USD120,342,000USD114,959,000USD116,026,000USD119,880,000USD
    Accounts Payable22,791,000USD18,925,000USD38,979,000USD62,743,000USD55,760,000USD45,978,000USD62,375,000USD56,560,000USD
    Property Plant Equipment Net171,245,000USD127,842,000USD89,333,000USD89,535,000USD98,530,000USD102,767,000USD90,718,000USD51,176,000USD
    Property Plant Equipment Gross260,113,000USD209,077,000USD161,693,000USD70,412,000USD71,300,000USD102,767,000USD90,718,000USD51,176,000USD
    Accumulated Other Comprehensive Income-28,368,000USD-37,659,000USD-34,495,000USD-31,564,000USD-19,032,000USD-19,801,000USD-44,161,000USD-25,747,000USD
    Common Stock Shares Outstanding48,720,000shares50,080,000shares50,178,000shares49,889,000shares50,842,000shares50,605,000shares51,140,000shares52,068,000shares
    Non Current Assets Total3,116,086,000USD2,953,890,000USD2,943,374,000USD2,961,986,000USD3,377,414,000USD3,159,438,000USD3,148,251,000USD3,140,098,000USD
    Non Current Liabilities Total1,539,130,000USD1,460,698,000USD1,546,285,000USD1,745,930,000USD1,949,648,000USD1,948,837,000USD2,193,053,000USD2,218,226,000USD
    Non Current Liabilities Other5,580,000USD5,391,000USD9,185,000USD11,543,000USD20,589,000USD26,522,000USD29,503,000USD20,053,000USD
    Non Currrent Assets Other2,170,000USD3,273,000USD5,725,000USD3,005,000USD3,273,000USD2,863,000USD2,963,000USD3,129,000USD
    Net Working Capital310,560,000USD341,705,000USD257,995,000USD231,028,000USD149,845,000USD147,697,000USD215,773,000USD173,959,000USD
    Unclassified Non Current Assets61,957,000USD———————
    Unclassified Current Liabilities-2,986,000USD——10,645,000USD2,664,000USD4,020,000USD5,127,000USD—
    Unclassified Non Current Liabilities539,597,000USD462,950,000USD411,296,000USD388,599,000USD————
    Unclassified Equity168,657,000USD315,634,000USD347,272,000USD345,694,000USD515,039,000USD498,968,000USD487,578,000USD478,614,000USD
    Other Assets—3,273,000USD1USD3,005,000USD3,273,000USD2,863,000USD2,963,000USD3,129,000USD
    Cash And Equivalents—97,884,000USD46,469,000USD58,489,000USD27,185,000USD32,302,000USD94,760,000USD27,530,000USD
    Current Deferred Revenue——2,569,000USD—————
    Net Tangible Assets———1,447,084,000USD1,577,611,000USD1,358,298,000USD1,170,971,000USD1,095,831,000USD
    Other Liab————452,401,000USD442,662,000USD428,838,000USD419,628,000USD
    Treasury Stock————-133,648,000USD-130,732,000USD-117,623,000USD-59,928,000USD
    Deferred Long Term Liab——————1,100,000USD800,000USD
    Unclassified Current Assets———————-4,741,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-06-30 · USDQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USD
    Net Income29,177,000USD53,928,000USD46,696,000USD42,211,000USD47,466,000USD50,128,000USD61,032,000USD54,377,000USD
    Depreciation8,753,000USD8,352,000USD7,592,000USD7,663,000USD7,666,000USD7,252,000USD6,868,000USD7,929,000USD
    Stock Based Compensation3,994,000USD2,647,000USD2,739,000USD1,767,000USD3,682,000USD2,733,000USD2,865,000USD2,134,000USD
    Deferred Income Tax193,000USD———————
    Other Non Cash Items13,089,000USD5,163,999USD39,536,000USD2,510,000USD2,389,000USD16,391,000USD2,326,000USD6,594,000USD
    Change To Account Receivables3,450,000USD-1,600,000USD495,000USD-29,923,000USD27,343,000USD-25,201,000USD-6,317,000USD8,823,000USD
    Change To Inventory-2,828,000USD5,472,000USD3,208,000USD-5,836,000USD-4,441,000USD4,071,000USD3,086,000USD-3,423,000USD
    Change To Liabilities23,234,000USD———————
    Change In Working Capital15,582,000USD-12,711,000USD4,935,000USD-14,049,000USD11,983,000USD-21,787,000USD-10,914,000USD-622,000USD
    Operating Cash Flow70,788,000USD———————
    Capital Expenditures-3,703,000USD-5,210,000USD-3,028,000USD-2,102,000USD-838,000USD-3,479,000USD-1,566,000USD-2,027,000USD
    Other Investing Activities-1,045,000,000USD———————
    Unclassified Investing Cash Flow-15,034,000USD1,796,000USD1,927,000USD2,929,000USD1,938,000USD12,707,000USD9,816,000USD3,005,000USD
    Investing Cash Flow-1,063,737,000USD———————
    Net Debt Issuance1,044,424,000USD———————
    Net Common Stock Issuance-2,661,000USD———————
    Other Financing Activities-1,486,000USD———————
    Unclassified Financing Cash Flow-21,823,000USD-9,174,000USD——————
    Financing Cash Flow1,018,454,000USD———————
    Effect Of Forex Changes On Cash-246,000USD———————
    Change In Cash25,259,000USD1,495,000USD-56,733,000USD-20,396,000USD41,618,000USD47,010,000USD-666,000USD17,284,000USD
    End Cash Flow89,127,000USD———————
    Total Cash From Operating Activities—50,622,000USD78,287,000USD57,486,000USD79,013,000USD61,848,000USD65,091,000USD69,800,000USD
    Free Cash Flow—45,412,000USD75,259,000USD55,384,000USD78,175,000USD58,369,000USD63,525,000USD67,773,000USD
    Total Cashflows From Investing Activities—-3,414,000USD-128,560,000USD-2,929,000USD-1,938,000USD-3,479,000USD-9,816,000USD-2,027,000USD
    Net Borrowings—-37,725,000USD39,376,000USD-539,000USD-608,000USD-2,637,000USD-60,211,000USD-40,968,000USD
    Total Cash From Financing Activities—-45,880,000USD-6,732,000USD-74,949,000USD-36,282,000USD-11,488,000USD-53,865,000USD-51,200,000USD
    Sale Purchase Of Stock—-690,000USD-45,818,000USD-75,000,000USD-34,775,000USD-11,313,000USD-2,402,000USD-11,818,000USD
    Begin Period Cash Flow—62,373,000USD119,106,000USD139,502,000USD97,884,000USD50,874,000USD51,540,000USD34,256,000USD
    End Period Cash Flow—63,868,000USD62,373,000USD119,106,000USD139,502,000USD97,884,000USD50,874,000USD51,540,000USD
    Other Cashflows From Financing Activities—1,709,000USD-290,000USD-162,000USD-899,000USD2,462,000USD8,748,000USD1,586,000USD
    Unclassified Operating Cash Flow—-6,757,999USD-23,211,000USD17,384,000USD5,827,000USD7,131,000USD2,914,000USD—
    Other Cashflows From Investing Activities——-127,459,000USD-827,000USD-1,100,000USD-9,228,000USD-8,250,000USD-978,000USD
    Investments———-2,929,000USD-1,938,000USD-3,479,000USD-9,816,000USD-2,027,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Net Income190,301,000USD214,605,000USD209,339,000USD-82,306,000USD205,381,000USD164,682,000USD142,281,000USD-35,800,000USD
    Depreciation31,273,000USD30,173,000USD30,675,000USD32,625,000USD32,092,000USD30,164,000USD28,995,000USD31,779,000USD
    Stock Based Compensation10,835,000USD11,157,000USD14,010,000USD12,405,000USD9,039,000USD8,543,000USD7,644,000USD7,438,000USD
    Other Non Cash Items30,979,000USD23,112,000USD11,663,000USD381,612,000USD14,377,000USD19,188,000USD15,550,000USD234,737,000USD
    Change To Account Receivables-3,685,000USD-16,327,000USD-6,322,000USD-24,927,000USD-24,654,000USD36,872,000USD-2,849,000USD-2,980,000USD
    Change To Inventory-1,597,000USD-9,314,000USD24,439,000USD-42,225,000USD663,000USD2,972,000USD2,930,000USD-10,535,000USD
    Change In Working Capital-9,842,000USD-41,941,000USD-39,831,000USD-53,855,000USD-10,946,000USD-5,598,000USD8,802,000USD-8,316,000USD
    Total Cash From Operating Activities265,408,000USD251,515,000USD248,926,000USD229,716,000USD259,922,000USD235,607,000USD217,124,000USD189,284,000USD
    Capital Expenditures-11,178,000USD-8,224,000USD-9,550,000USD-7,784,000USD-9,642,000USD-22,243,000USD-14,560,000USD-10,480,000USD
    Free Cash Flow254,230,000USD243,291,000USD239,376,000USD221,932,000USD250,280,000USD213,364,000USD202,564,000USD178,804,000USD
    Total Cashflows From Investing Activities-136,841,000USD-17,452,000USD-20,111,000USD-11,584,000USD-256,511,000USD-22,243,000USD-16,570,000USD55,432,000USD
    Net Borrowings504,000USD-139,536,000USD-227,827,000USD-135,000,000USD-9,111,000USD-267,718,000USD-74,584,000USD-200,000,000USD
    Total Cash From Financing Activities-163,843,000USD-182,075,000USD-241,015,000USD-185,846,000USD-7,569,000USD-279,419,000USD-131,431,000USD-249,328,000USD
    Sale Purchase Of Stock-156,283,000USD-51,509,000USD-25,000,000USD-50,000,000USD-2,916,000USD-11,867,000USD-56,721,000USD-49,978,000USD
    Change In Cash-34,016,000USD51,415,000USD-12,020,000USD31,304,000USD-5,117,000USD-62,458,000USD67,230,000USD-5,018,000USD
    Begin Period Cash Flow97,884,000USD46,469,000USD58,489,000USD27,185,000USD32,302,000USD94,760,000USD27,530,000USD32,548,000USD
    End Period Cash Flow63,868,000USD97,884,000USD46,469,000USD58,489,000USD27,185,000USD32,302,000USD94,760,000USD27,530,000USD
    Other Cashflows From Investing Activities-1,927,000USD-9,228,000USD-10,561,000USD-3,800,000USD177,000USD177,000USD750,000USD65,912,000USD
    Other Cashflows From Financing Activities-4,567,999USD-5,832,000USD11,812,000USD1,906,000USD-1,987,000USD-16,109,000USD-6,234,000USD650,000USD
    Unclassified Operating Cash Flow11,862,000USD14,409,000USD23,070,000USD-60,765,000USD9,979,000USD18,628,000USD13,852,000USD-40,554,000USD
    Unclassified Investing Cash Flow-123,736,000USD17,452,000USD20,111,000USD11,584,000USD9,465,000USD22,066,000USD13,810,000USD-55,432,000USD
    Unclassified Financing Cash Flow-3,496,001USD14,802,000USD—-2,752,000USD10,569,000USD19,126,000USD7,432,000USD2,931,000USD
    Investments—-17,452,000USD-20,111,000USD-11,584,000USD-256,511,000USD-22,243,000USD-16,570,000USD55,432,000USD
    Change To Liabilities———18,000,000USD18,770,000USD-32,254,000USD18,306,000USD-259,000USD
    Cash And Cash Equivalents Changes———32,286,000USD-4,158,000USD-66,055,000USD69,123,000USD-4,612,000USD
    Dividends Paid————-4,124,000USD-2,851,000USD-1,324,000USD-2,931,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2027Quarterly · 2026-06-30ProductCough Cold And Allergy21,305,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductDermatologicals33,195,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductEye And Ear Care32,978,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductGastrointestinal62,202,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductOral Care22,358,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductPain Relief26,802,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductWellness Sleep Other14,327,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30ProductWomens Health52,543,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30SegmentInternational OTCHealthcare39,504,000USDDisclosure
    Q1 2027Quarterly · 2026-06-30SegmentNorth American OTCHealthcare226,206,000USDDisclosure
    Q4 2026Quarterly · 2026-03-31ProductAnalgesics28,238,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductCough And Cold26,290,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductDermatologicals30,488,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductEye And Ear Care37,854,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductGastrointestinal68,350,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductOral Care27,998,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductOther Otc5,353,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductWomens Health57,046,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31SegmentInternational OTCHealthcare47,072,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31SegmentNorth American OTCHealthcare234,545,000USDLegacy provider
    FY 2026Yearly · 2026-03-31GeographyInternational238,291,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31GeographyUnited States850,414,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductAnalgesics113,936,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductCough And Cold101,909,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductDermatologicals125,931,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductEye And Ear Care142,939,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductGastrointestinal259,788,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductOral Care101,051,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductOther Otc15,386,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31ProductWomens Health227,765,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31SegmentInternational OTCHealthcare175,129,000USD0001295947-26-000016
    FY 2026Yearly · 2026-03-31SegmentNorth American OTCHealthcare913,576,000USD0001295947-26-000016
    Q3 2026Quarterly · 2025-12-31ProductAnalgesics28,033,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductCough And Cold29,327,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductDermatologicals29,638,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductEye And Ear Care38,600,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductGastrointestinal69,454,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductOral Care26,584,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductOther Otc4,043,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31ProductWomens Health57,765,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31SegmentInternational OTCHealthcare47,747,000USD0001295947-26-000008
    Q3 2026Quarterly · 2025-12-31SegmentNorth American OTCHealthcare235,697,000USD0001295947-26-000008
    Q2 2026Quarterly · 2025-09-30ProductAnalgesics28,733,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductCough And Cold27,285,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductDermatologicals35,696,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductEye And Ear Care34,177,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductGastrointestinal64,200,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductOral Care24,767,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductOther Otc3,060,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30ProductWomens Health56,196,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30SegmentInternational OTCHealthcare43,358,000USD0001295947-25-000039
    Q2 2026Quarterly · 2025-09-30SegmentNorth American OTCHealthcare230,756,000USD0001295947-25-000039
    Q1 2026Quarterly · 2025-06-30ProductAnalgesics28,932,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductCough And Cold19,007,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductDermatologicals30,109,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductEye And Ear Care32,308,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductGastrointestinal57,784,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductOral Care21,702,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductOther Otc2,930,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30ProductWomens Health56,758,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30SegmentInternational OTCHealthcare36,952,000USD0001295947-25-000029
    Q1 2026Quarterly · 2025-06-30SegmentNorth American OTCHealthcare212,578,000USD0001295947-25-000029
    Q4 2025Quarterly · 2025-03-31ProductAnalgesics30,200,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductCough And Cold26,911,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductDermatologicals29,082,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductEye And Ear Care46,728,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductGastrointestinal68,877,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductOral Care27,093,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductOther Otc3,846,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductWomens Health63,781,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31SegmentInternational OTCHealthcare47,569,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31SegmentNorth American OTCHealthcare248,949,000USDLegacy provider
    FY 2025Yearly · 2025-03-31GeographyInternational240,222,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31GeographyUnited States897,540,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductAnalgesics117,697,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductCough And Cold106,214,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductDermatologicals128,947,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductEye And Ear Care183,322,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductGastrointestinal255,943,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductOral Care95,030,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductOther Otc13,778,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31ProductWomens Health236,831,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31SegmentInternational OTCHealthcare177,752,000USD0001295947-26-000016
    FY 2025Yearly · 2025-03-31SegmentNorth American OTCHealthcare960,010,000USD0001295947-26-000016
    Q3 2025Quarterly · 2024-12-31ProductAnalgesics30,982,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductCough And Cold29,331,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductDermatologicals30,655,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductEye And Ear Care45,678,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductGastrointestinal68,990,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductOral Care23,080,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductOther Otc3,476,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31ProductWomens Health58,125,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31SegmentInternational OTCHealthcare51,383,000USD0001295947-26-000008
    Q3 2025Quarterly · 2024-12-31SegmentNorth American OTCHealthcare238,934,000USD0001295947-26-000008
    Q2 2025Quarterly · 2024-09-30ProductAnalgesics28,222,000USD0001295947-25-000039
    Q2 2025Quarterly · 2024-09-30ProductCough And Cold29,275,000USD0001295947-25-000039
    Q2 2025Quarterly · 2024-09-30ProductDermatologicals35,855,000USD0001295947-25-000039
    Q2 2025Quarterly · 2024-09-30ProductEye And Ear Care42,786,000USD0001295947-25-000039
    Q2 2025Quarterly · 2024-09-30ProductGastrointestinal60,061,000USD0001295947-25-000039
    Q2 2025Quarterly · 2024-09-30ProductOral Care24,083,000USD0001295947-25-000039

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.